1 | microscopic and macroscopic methods | | | | | | | 7 | 1.24% |
2 | quality standards of every | | | | | | | 7 | 1.24% |
3 | pharmaceutics to ensure new | | | | | | | 7 | 1.24% |
4 | to ensure new formations | | | | | | | 7 | 1.24% |
5 | ensure new formations presentations | | | | | | | 7 | 1.24% |
6 | new formations presentations and | | | | | | | 7 | 1.24% |
7 | dosage for each medicine | | | | | | | 7 | 1.24% |
8 | pharmacognosy to identify authentication | | | | | | | 7 | 1.24% |
9 | to identify authentication raw | | | | | | | 7 | 1.24% |
10 | preprocess inprocess and postprocess | | | | | | | 7 | 1.24% |
11 | microbiologyto ensures the absence | | | | | | | 7 | 1.24% |
12 | ayurvedic products to standardize | | | | | | | 7 | 1.24% |
13 | fermentation to identify herbs | | | | | | | 7 | 1.24% |
14 | chemistry – to ensure | | | | | | | 7 | 1.24% |
15 | identify authentication raw materials | | | | | | | 7 | 1.24% |
16 | authentication raw materials through | | | | | | | 7 | 1.24% |
17 | of microbial contamination in | | | | | | | 7 | 1.24% |
18 | standardize fermentation to identify | | | | | | | 6 | 1.06% |
19 | have good antibacterialantifungal properties | | | | | | | 6 | 1.06% |
20 | to standardize fermentation to | | | | | | | 6 | 1.06% |
21 | products to standardize fermentation | | | | | | | 6 | 1.06% |
22 | ensures the absence of | | | | | | | 6 | 1.06% |
23 | formations presentations and optimum | | | | | | | 6 | 1.06% |
24 | the absence of microbial | | | | | | | 6 | 1.06% |
25 | standards of every product | | | | | | | 6 | 1.06% |
26 | absence of microbial contamination | | | | | | | 6 | 1.06% |
27 | – to ensure preprocess | | | | | | | 6 | 1.06% |
28 | to ensure preprocess inprocess | | | | | | | 6 | 1.06% |
29 | ensure preprocess inprocess and | | | | | | | 6 | 1.06% |
30 | clinical research – to | | | | | | | 5 | 0.88% |
31 | phases of clinical trials | | | | | | | 5 | 0.88% |
32 | clinics using epidemiological parameters | | | | | | | 5 | 0.88% |
33 | actual patient at our | | | | | | | 5 | 0.88% |
34 | an actual patient at | | | | | | | 5 | 0.88% |
35 | of clinical trials on | | | | | | | 5 | 0.88% |
36 | various phases of clinical | | | | | | | 5 | 0.88% |
37 | pharmacologyto scientifically evaluates the | | | | | | | 5 | 0.88% |
38 | scientifically evaluates the efficacy | | | | | | | 5 | 0.88% |
39 | conduct various phases of | | | | | | | 5 | 0.88% |
40 | dosage of herbal formulations | | | | | | | 5 | 0.88% |